Mga Klase ng Cardiopulmonary na Gamot at Implikasyon sa Nursing
Mahahalagang Punto
- Pangunahing pinapabuti ng respiratory drugs ang oxygenation at ventilation sa pamamagitan ng bronchodilation, pagbawas ng inflammation, o secretion/cough control.
- Binabago ng cardiac drugs ang preload, afterload, rhythm, rate, contractility, lipid burden, at fluid status.
- Nangangailangan ang ligtas na administration ng class-specific monitoring ng vital signs, rhythm, perfusion, fluid balance, at adverse effects.
- Dapat i-reassess ang medication response gamit ang symptom trends, objective data, at escalation kapag lumitaw ang instability.
Patopisyolohiya
Karaniwang pinagsasama ng cardiopulmonary disorders ang airway resistance, inflammation, gas-exchange impairment, perfusion mismatch, dysrhythmia risk, at hemodynamic stress. Ang drug therapy ay tumatarget sa isa o higit pa sa mga driver na ito.
Nakatuon ang respiratory classes sa airway caliber, inflammatory control, at secretion handling. Nakatuon ang cardiac classes sa vascular tone, myocardial workload, electrical conduction, at volume management.
Pag-uuri
- Respiratory bronchodilator classes: beta2 agonists (halimbawa albuterol), anticholinergics (halimbawa ipratropium o tiotropium), at methylxanthines (halimbawa theophylline).
- Respiratory anti-inflammatory classes: corticosteroids, leukotriene receptor antagonists (halimbawa montelukast), at mast-cell stabilizers (halimbawa cromolyn).
- Respiratory symptom-control classes: antihistamines, decongestants, expectorants (halimbawa guaifenesin), antitussives (halimbawa dextromethorphan), at anti-infectives na pinipili batay sa organism data kapag available.
- Cardiac hemodynamic classes: ACE inhibitors, ARBs, nitrates, beta blockers, calcium-channel blockers, catecholamines, neprilysin/ARB combination therapy, at diuretics.
- Cardiac rhythm and contractility classes: adenosine, potassium-channel blockers (halimbawa amiodarone), sodium-channel blockers (halimbawa lidocaine), at cardiac glycosides (halimbawa digoxin).
- Cardiovascular risk-modification classes: HMG-CoA reductase inhibitors (statins).
Pagtatasa sa Nursing
Pokus sa NCLEX
Kabilang sa mga prayoridad ang pagtukoy ng unstable vital-sign trends, rhythm changes, at adverse effects na nangangailangan ng mabilis na escalation.
- Tayahin ang baseline at trend ng heart rate, blood pressure, oxygen saturation, respiratory effort, at mental status bago at pagkatapos ng administration.
- Tayahin ang ECG rhythm context para sa antiarrhythmic o rate-modifying therapy.
- Tayahin ang fluid status, urine output, at edema pattern kasama ng diuretic o heart-failure regimens.
- Tayahin ang lung sounds, cough effectiveness, at work of breathing kapag tine-titrate ang respiratory medications.
- Tayahin ang adverse-effect cues gaya ng hypotension, bradycardia, bagong dysrhythmia, bronchospasm, electrolyte shift signs, at reduced perfusion.
- Sa pediatric CHD medication plans, i-verify kung dapat isara ang ductal patency (NSAID/acetaminophen pathways) o panatilihin (prostaglandin E1 infusion bridge) bago kumilos sa PDA-focused orders.
Mga Interbensyon sa Nursing
- I-verify ang indication, class, route, timing, at safety parameters bago administration.
- Ipares ang respiratory medications sa breathing-support interventions at focused reassessment.
- Ipares ang cardiac medications sa hemodynamic at rhythm surveillance batay sa class risk.
- Gumamit ng mahigpit na intake/output at daily-weight trending kapag aktibo ang volume-targeted therapy.
- Para sa digoxin-containing regimens, tasahin ang apical pulse sa buong isang minuto bago dosing at i-monitor ang potassium/magnesium trends upang mabawasan ang toxicity risk.
- Agarang mag-escalate kapag wala ang medication response o kapag lumilitaw ang deterioration.
- Palakasin ang patient teaching tungkol sa layunin, inaasahang effect, common adverse effects, at kung kailan hihingi ng agarang tulong.
Polypharmacy at Panganib ng Instability
Maaaring magdulot ng mabilis na physiologic shifts ang maraming cardiopulmonary drug classes. Mahalaga ang trend-based reassessment pagkatapos ng bawat clinically meaningful na pagbabago.
Farmakolohiya
| Class Group | Representative Drugs | Core Mechanism | Nursing Priority |
|---|---|---|---|
| Bronchodilators | Albuterol, ipratropium, tiotropium, theophylline | Bawasan ang bronchoconstriction at pahusayin ang airflow | Muling tasahin ang breath sounds, dyspnea, at oxygenation pagkatapos ng dosing |
| Respiratory anti-inflammatory agents | Corticosteroids, montelukast, cromolyn | Bawasan ang inflammatory airway reactivity | Subaybayan ang symptom reduction at rescue-medication need |
| Cough/secretion symptom agents | Guaifenesin, dextromethorphan | Palabnawin ang secretions o supilin ang cough reflex | Balansehin ang secretion mobilization sa ginhawa at pahinga |
| Renin-angiotensin pathway modifiers | ACE inhibitors, ARBs, sacubitril/valsartan | Bawasan ang vasoconstriction at maladaptive remodeling | I-monitor ang blood pressure, perfusion, at tolerance |
| Antianginal/vascular classes | Nitroglycerin, calcium-channel blockers, beta blockers | Bawasan ang oxygen demand at pahusayin ang perfusion | I-monitor ang chest-pain response at hemodynamic stability |
| Rhythm-focused classes | Adenosine, amiodarone, lidocaine, digoxin | Baguhin ang conduction, repolarization, at contractility | Continuous rhythm monitoring sa unstable settings |
| Volume and lipid management | Furosemide, spironolactone, hydrochlorothiazide, statins | Isulong ang fluid removal o pababain ang LDL burden | I-trend ang fluid balance, electrolytes, at longer-term risk markers |
Aplikasyon ng Clinical Judgment
Klinikal na Sitwasyon
Ang pasyenteng may acute dyspnea at edema ay tumatanggap ng bronchodilator therapy, loop diuretic therapy, at antihypertensive treatment sa loob ng parehong shift.
- Recognize Cues: Patuloy na work of breathing, tumataas na heart rate, at nagbabagong blood pressure matapos ang treatment.
- Analyze Cues: Ang mixed airway at hemodynamic pathology ay nangangailangan ng magkasabay na monitoring ng respiratory at cardiac responses.
- Prioritize Hypotheses: Hindi sapat na response laban sa umuusbong na medication adverse effects.
- Generate Solutions: Muling tasahin ang oxygenation, lung findings, rhythm, at fluid response; maghanda para sa escalation.
- Take Action: I-report ang trend deterioration at i-coordinate ang mabilis na treatment adjustment.
- Evaluate Outcomes: Bumubuti ang sintomas kasabay ng stabilized vitals, mas maayos na oxygenation, at pinabuting fluid/perfusion markers.
Kaugnay na Konsepto
- pagpili at monitoring ng oxygen therapy device - Dapat nakaayon ang oxygen delivery sa nagbabagong drug response.
- therapeutic breathing techniques para sa cardiopulmonary care - Pinapahusay ng nonpharmacologic support ang bisa ng respiratory medications.
- heart failure - Maraming cardiac classes sa note na ito ay core heart-failure therapies.
- coronary artery disease - Sinusuportahan ng antianginal at lipid-lowering classes ang CAD management.
- medication-induced cardiopulmonary adverse effects - Mahalaga ang adverse-effect surveillance sa multi-drug cardiopulmonary care.
Sariling Pagsusuri
- Aling bedside trends ang nakatutulong para ihiwalay ang drug benefit sa maagang adverse effects sa cardiopulmonary care?
- Bakit dapat ipares ang rhythm at hemodynamic reassessment pagkatapos ng antiarrhythmic at vasoactive therapy?
- Paano binabago ng pagsasama ng respiratory at cardiac medication classes ang nursing monitoring priorities?